62577-90-6 Usage
Description
4-Cyclopropoxy-benzoic acid is an organic compound characterized by the presence of a cyclopropane ring and a benzene ring connected through an oxygen atom. It is a key intermediate in the synthesis of various pharmaceutical compounds and has demonstrated potential in the treatment of metabolic disorders.
Uses
Used in Pharmaceutical Industry:
4-Cyclopropyloxybenzoic Acid is used as a key intermediate for the preparation of imidazobenzazepine derivatives, which act as DGAT-1 inhibitors. These inhibitors are crucial in the treatment of diabetes and obesity, as they help regulate the synthesis of triglycerides and modulate lipid metabolism, thus contributing to the management of these metabolic disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 62577-90-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,2,5,7 and 7 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 62577-90:
(7*6)+(6*2)+(5*5)+(4*7)+(3*7)+(2*9)+(1*0)=146
146 % 10 = 6
So 62577-90-6 is a valid CAS Registry Number.
62577-90-6Relevant articles and documents
S1P1 AGONIST AND APPLICATION THEREOF
-
, (2021/10/02)
The present invention relates to a class of tricyclic compounds and an application thereof as a sphingosine 1-phosphate type 1 (S1P1) receptor agonist. The invention specifically relates to a compound represented by formula (II), and a tautomer and pharmaceutically acceptable salt of same.
PPAR AGONISTS AND METHODS OF USE THEREOF
-
, (2016/05/02)
Provided herein are deuterated compounds and compositions useful in increasing PPAR5 activity. The compounds and compositions provided herein are useful for the treatment of PPAR5 related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
PPAR AGONISTS
-
, (2014/10/18)
Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
